Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The GLP-1 Revolution Driving Growth Lilly dominates the obesity and diabetes market with two blockbuster drugs that are rewriting treatment paradigms: Mounjaro (Type 2 Diabetes) + Zepbound (Obesity) = $10.1B in Q3 2025 revenues (+131% YoY) Mounjaro: $6.52B (+109% YoY) Zepbound: $3.59B (+184% YoY) For context: This tirzepatide franchise just surpassed Merck's Keytruda ($8.1B in Q3) to become the world's best-selling drug
In fact, there is a real need for food and beverage businesses to help educate consumers here, as while the jabs help shed weight, they do not encourage users to eat well for long-term health
What is the Bridge program
She said she doubted coverage would be reinstated down the line, because once a budgetary cut is made, other things fill that gap. For me, its like, whats next? Murphy-Rodrigues said
US$ 24.96
US$ 27.78
US$ 27.39
US$ 23.60
US$ 36745.00
Sold : Login>>
